表紙
市場調査レポート

世界における黄斑浮腫市場

Global Macular Edema Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 307868
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
世界における黄斑浮腫市場 Global Macular Edema Market 2014-2018
出版日: 2014年07月07日 ページ情報: 英文 83 Pages
概要

黄斑浮腫は、網膜の黄斑部に液状の成分がたまることによって発症します。同疾患の罹患原因には、糖尿病、加齢黄斑変性(AMD)、網膜静脈閉塞症(RVO)などがあります。世界の黄斑浮腫市場は、2013年から2018年にかけて、9.1%のCAGRで拡大することが見込まれています。

当レポートでは、世界における黄斑浮腫市場の動向と将来の成長見通し、治療タイプ別の動向、市場の成長因子と課題、主要ベンダーの情報などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 疾患の概要

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • 主要薬剤の市場分析
    • Lucentis
    • Eylea
  • その他の有望な薬剤の市場分析
    • Ozurdex
    • Iluvien
  • ファイブフォース分析

第8章 分子タイプ別の市場区分

組換えタンパク質 小分子

第9章 地理区分

第10章 購入基準

第11章 市場成長因子

第12章 成長因子とその影響

第13章 市場の課題

第14章 成長因子と課題の影響

第15章 市場動向

第16章 動向とその影響

第17章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第18章 主要ベンダーの分析

  • Bayer AG
  • F. Hoffmann La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

第19章 関連レポート

目次
Product Code: IRTNTR3767

About Macular Edema

Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

TechNavio's analysts forecast the Global Macular Edema market will grow at a CAGR of 9.1 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Macular Edema market for the period 2013-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat macular edema associated with distinct etiologies.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Macular Edema market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Macular Edema Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Macular Edema market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alcon Inc.
  • Alimera Sciences Inc.
  • Allergan Inc.
  • Ampio Pharmaceuticals Inc.
  • iCo Therapeutics Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.

Key Market Driver

  • Increase in Patient Population

For a full, detailed list, view our report.

Key Market Challenge

  • Increasing Use of Off-label Drugs

For a full, detailed list, view our report.

Key Market Trend

  • Increasing Recommendations by NICE

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Market Analysis of Major Drugs
    • 07.3.1. Lucentis
    • 07.3.2. Eylea
  • 07.4. Market Analysis of Other Prominent Drugs
    • 07.4.1. Ozurdex
    • 07.4.2. Iluvien
  • 07.5. Five Forces Analysis

08. Market Segmentation by Molecule Type

  • 08.1.1. Recombinant Protein
  • 08.1.2. Small Molecule

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors and Future Vendors

18. Key Vendor Analysis

  • 18.1. Bayer AG
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Information
    • 18.1.8. SWOT Analysis
    • 18.1.9. Strengths
    • 18.1.10. Weaknesses
    • 18.1.11. Opportunities
    • 18.1.12. Threats
  • 18.2. F. Hoffmann La Roche Ltd.
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Segmentation by Revenue 2012 and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Business Strategy
    • 18.2.7. Key Information
    • 18.2.8. SWOT Analysis
    • 18.2.9. Strengths
    • 18.2.10. Weaknesses
    • 18.2.11. Opportunities
    • 18.2.12. Threats
  • 18.3. Novartis AG
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis
    • 18.3.9. Strengths
    • 18.3.10. Weaknesses
    • 18.3.11. Opportunities
    • 18.3.12. Threats
  • 18.4. Regeneron Pharmaceuticals Inc.
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Product Segmentation
    • 18.4.4. Revenue Product Segmentation
    • 18.4.5. Business Strategy
    • 18.4.6. Key Information
    • 18.4.7. SWOT Analysis
    • 18.4.8. Strengths
    • 18.4.9. Weaknesses
    • 18.4.10. Opportunities
    • 18.4.11. Threats

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Macular Edema Market 2013-2018 (US$ billion)
  • Exhibit 3: Timeline of Key Regulatory Approvals of Lucentis
  • Exhibit 4: Geography-wise Segmentation of Lucentis Sales (US$ million)
  • Exhibit 5: Lucentis' Revenue 2006-2013 (US$ million)
  • Exhibit 6: Timeline of Key Regulatory Approvals and Filings of Eylea
  • Exhibit 7: Geography-wise Segmentation of Eylea Sales (US$ million)
  • Exhibit 8: Eylea's Revenue 2011-2013 (US$ million)
  • Exhibit 9: Global Macular Edema Market Segmentation by Molecule Type
  • Exhibit 10: Global Macular Edema Market by Geographical Segmentation 2013
  • Exhibit 11: Global Macular Edema Market Share Analysis 2013
  • Exhibit 12: Bayer AG: Business Segmentation 2013
  • Exhibit 13: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 14: Bayer AG: Sales by Geography 2013
  • Exhibit 15: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 17: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 18: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 19: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 20: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: Novartis AG: Sales by Geography 2013
  • Exhibit 22: Regeneron Pharmaceuticals Inc.: Product Segmentation
  • Exhibit 23: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
Back to Top